s6y

Oaktree Acquisition Corp. III Life Sciences

Ticker
OACC, OACCU, OACCW
CIK
2029769
Industry
Blank Checks

Financials 8

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024

News 11

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 11 news filings

Ownership 15

  1. 4 Statement of changes in beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. SC 13G Major Shareholders
  6. 4 Statement of changes in beneficial ownership of securities
  7. SC 13G Major Shareholders
  8. 3 Initial statement of beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 15 ownership filings

Prospectus 6

  1. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  2. S-1/A General form of registration statement for all companies including face-amount certificate companies
  3. S-1 General form of registration statement for all companies including face-amount certificate companies
  4. DRSLTR Correspondence Related to Draft Registration Statement
  5. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  6. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Proxies 4

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

Other 25

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G
  4. SCHEDULE 13G
  5. SCHEDULE 13G
  6. SCHEDULE 13G
  7. SCHEDULE 13G/A
  8. SCHEDULE 13G/A
  9. SCHEDULE 13G/A
  10. SCHEDULE 13G/A

All 25 other filings